The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)
Sponsored by The Baruch Padeh Medical Center, Poriya
About this trial
Last updated 12 years ago
Study ID
Leuveris1.CTIL
Status
Completed
Type
Interventional
Phase
Phase 4
Placebo
No
Accepting
25 to 45 Years
Female
Trial Timing
Ended 13 years ago
What is this trial about?
To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.
What are the participation requirements?
Inclusion Criteria
* female candidate to IVF
* between 30-45 years old
Exclusion Criteria
* not included for fertilization